Healthcare Industry News: Alzheimer's
News Release - November 29, 2006
Stem Cell Therapy International Reports the Successful Treatment of a Stroke Patient With Their Proprietary Stem Cell Transplantation TherapyTAMPA, FL--(Healthcare Sales & Marketing Network)--Nov 29, 2006 -- Stem Cell Therapy International, Inc. (Other OTC:SCII.PK ), a company in the field of research and development of stem cell transplantation therapy and regenerative medicine, announced today the successful treatment of a stroke patient from the United States with its stem cell transplantation therapy protocol conducted at one of their affiliate clinics in Kiev, Ukraine.
Dr. Rich James, 50, a practicing Chiropractor in New York City, whose left arm and left leg were paralyzed as a result of a stroke that he suffered in February of 2006, had undergone traditional medical treatment available for stroke survivors here in the US with only limited results.
Dr. James said, "I realized that I could live for another thirty years. I did not want to live with the crippling effects of my stroke. Physical therapy and occupational therapy could only do so much in helping me get the function back on my paralyzed side."
Dr. James, after his stroke, became a member of the on-line global stroke survivor support community StrokeNetwork.org and was able to contact Stem Cell Therapy International from the information posted by SCTI on their website with the permission of Steve Mallory, the founder, President and CEO of the StrokeNetwork.
Steve Mallory stated his reasons for creating the StrokeNetwork: "I founded the on-line stroke support network so that we are available to everybody around the world on a 24/7 basis. Our mission is to provide on-line stroke support to all adult stroke survivors and also to stroke caregivers."
Mr. Mallory goes on to say, "In the future, I foresee stem cell transplantation therapy being used by stroke survivors to regain physical improvements on some of the deficits caused by their stroke. The resulting effects will definitely improve their 'quality of life.'"
Calvin Cao, CEO of Stem Cell Therapy International, said, "After his stroke Dr. James was in a wheelchair but could walk short distances with the aid of an AFO and a quad cane. He traveled to our affiliate clinic in Kiev and received stem cell transplantation therapy as well as physical and massage therapy. At six weeks post treatment, Dr. James can walk without any aids and at four months post treatment he is now able to take the NY subway on his own to get around."
Mr. Cao said, "Dr. James has been posting a blog journal about his experience in having the stroke and the support of the members of the StrokeNetwork and Stem Cell Therapy International. We invite everyone to log on to our website at www.scticorp.com, click on the 'In The Spotlight' section and read the comments from Dr. James about his continuing recovery from his stroke after stem cell transplantation therapy."
Stem cell transplantation therapy is a field of medicine, which uses techniques and technologies that rely on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. The SCTI proprietary therapy is similar to the process of organ transplantation, only the treatment consists of the transplantation of stem cells into the body rather than entire organs, thus eliminating any chance of rejection or the need for expensive and potentially dangerous immunosuppression drug therapy. These new techniques are being applied to finding a cure for a wide range of human disorders in SCTI affiliated medical facilities outside of the United States.
With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to fund stem cell research. Since then a number of other states such as New Jersey, Massachusetts, Connecticut, Illinois and Wisconsin, have allocated funds for additional stem cell research in the US.
About Stem Cell Therapy International (SCTI)
Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the treatment of patients with stem cell transplantation therapy. SCTI manufactures the stem cell biological solutions that is currently being used in the treatment of patients suffering from degenerative disorders of the human body such as Alzheimer's, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer. The Company has established license agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI plans to provide these stem cell biological solutions to universities, institutes and privately funded laboratory facilities in the United States for research purposes and clinical trials. Its products, which are available now for treatment, include various stem cell biological solutions which contain human stem cells, low-molecular proteins and human growth factor hormones.
This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.
Source: Stem Cell Therapy International
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.